Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Persistence and Immune Response to a Booster Dose of MenACWY

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy adolescents or adults (age 16-23 years inclusive), either previously enrolled in the parent study or naïve to meningococcal vaccination.~* Female subjects were to be negative for pregnancy~Exclusion Criteria:~* History of meningococcal disease~* Receipt of any meningococcal vaccine outside of parent study (V59P6)~* Serious, acute, or chronic illnesses including HIV infection/disease and any malignancy~* receipt of any vaccine 14 days prior to the study, or expected through the duration of the study~* any condition which in the eyes of the investigator would pose a health risk to the subject or render them inappropriate for a research study

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 23 Years
- Healthy Volunteers: t

Study Arms:
- I: MenACWY-CRM vaccine (Type: EXPERIMENTAL): Subjects had been given one dose of Meningococcal ACWY (MenACWY) vaccine conjugated to CRM197 (cross-reactive material-mutant of diptheria toxin) 5 years ago. All subjects were given one dose of the Men ACWY in the present study.
- II: Licensed Polysaccharide Meningococcal vaccine (Type: EXPERIMENTAL): Subjects had been given one dose of a licensed MenACWY polysaccharide meningococcal vaccine (Menomune) 5 years ago. All subjects were given one dose of Men ACWY vaccine in the present study.
- III: Meningococcal Naive (Type: EXPERIMENTAL): Subjects were age matched with groups 1 and 2 (age inclusive: 16 years to 23 years) and enrolled at visit 1 and given one dose of Men ACWY vaccine during the present study.

Based on this trial design, predict the completion outcome and termination type (if applicable).